Longtime biotech investor injects $250M into Palo Alto company a year after IPO

Kodiak Sciences is in a pivotal trial with its lead drug against a blinding eye disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.